TY  - CONF
AU  - Dinić, Jelena
AU  - Podolski-Renić, Ana
AU  - Stanković, Tijana
AU  - Botta, Maurizio
AU  - Pešić, Milica
PY  - 2019
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6040
AB  - P-glycoprotein (P-gp) is an ATP-binding cassette (ABC) transporter whose
overexpression in cancer cells is one of the main causes of multidrug resistance (MDR).
P-gp overexpression is responsible for reduced intracellular accumulation and efficacy
of both targeted therapies and classic chemotherapeutics. Therefore, P-gp has an
important role in "absorption, distribution, metabolism, and excretion" – ADME
studies. It is also considered as the first cellular defense line and a part of so-called
“cellular immunity’. Tyrosine kinase inhibitors (TKIs) have been reported to interact
with ABC transporters, and in some cases increase the susceptibility of cancer cells to
chemotherapy. We have investigated the anticancer potential of novel tyrosine kinase
inhibitors pyrazolo[3,4-d] pyrimidines and their prodrugs against two pairs of sensitive
and MDR cancer cell lines with P-gp overexpression: non-small cell lung carcinoma
(NCI-H460 and NCI-H460/R) and colorectal carcinoma (DLD1 and DLD1-TxR). The
tested compounds displayed significant cell growth inhibition and enhanced the
efficacy of doxorubicin and paclitaxel in MDR cancer cells. Some of the TKIs directly
interacted with P-gp and inhibited its ATPase activity. A kinetics study showed that the
compounds increased the intracellular accumulation of the P-gp substrate rhodamine
123 in a time-dependent manner. Treatment with the compounds did not increase the
mRNA expression level of P-gp in resistant cancer cells. The investigated pyrazolo[3,4-
d] pyrimidines showed significant potential for reversing P-gp-mediated MDR even in
prolonged treatment, making them good candidates for further development regarding
treatment of resistant cancers.
PB  - Belgrade: Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade
C3  - Immunology at the Confluence of Multidisciplinary Approaches: abstract book: 2019 Dec 6-8; Belgrade, Serbia
T1  - Novel pyrazolo[3,4-d]pyrimidine derivatives supress P-glycoprotein activity and reverse multidrug resistance in cancer cells
SP  - 122
EP  - 122
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_6040
ER  - 

@conference{
author = "Dinić, Jelena and Podolski-Renić, Ana and Stanković, Tijana and Botta, Maurizio and Pešić, Milica",
year = "2019",
abstract = "P-glycoprotein (P-gp) is an ATP-binding cassette (ABC) transporter whose
overexpression in cancer cells is one of the main causes of multidrug resistance (MDR).
P-gp overexpression is responsible for reduced intracellular accumulation and efficacy
of both targeted therapies and classic chemotherapeutics. Therefore, P-gp has an
important role in "absorption, distribution, metabolism, and excretion" – ADME
studies. It is also considered as the first cellular defense line and a part of so-called
“cellular immunity’. Tyrosine kinase inhibitors (TKIs) have been reported to interact
with ABC transporters, and in some cases increase the susceptibility of cancer cells to
chemotherapy. We have investigated the anticancer potential of novel tyrosine kinase
inhibitors pyrazolo[3,4-d] pyrimidines and their prodrugs against two pairs of sensitive
and MDR cancer cell lines with P-gp overexpression: non-small cell lung carcinoma
(NCI-H460 and NCI-H460/R) and colorectal carcinoma (DLD1 and DLD1-TxR). The
tested compounds displayed significant cell growth inhibition and enhanced the
efficacy of doxorubicin and paclitaxel in MDR cancer cells. Some of the TKIs directly
interacted with P-gp and inhibited its ATPase activity. A kinetics study showed that the
compounds increased the intracellular accumulation of the P-gp substrate rhodamine
123 in a time-dependent manner. Treatment with the compounds did not increase the
mRNA expression level of P-gp in resistant cancer cells. The investigated pyrazolo[3,4-
d] pyrimidines showed significant potential for reversing P-gp-mediated MDR even in
prolonged treatment, making them good candidates for further development regarding
treatment of resistant cancers.",
publisher = "Belgrade: Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade",
journal = "Immunology at the Confluence of Multidisciplinary Approaches: abstract book: 2019 Dec 6-8; Belgrade, Serbia",
title = "Novel pyrazolo[3,4-d]pyrimidine derivatives supress P-glycoprotein activity and reverse multidrug resistance in cancer cells",
pages = "122-122",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_6040"
}

Dinić, J., Podolski-Renić, A., Stanković, T., Botta, M.,& Pešić, M.. (2019). Novel pyrazolo[3,4-d]pyrimidine derivatives supress P-glycoprotein activity and reverse multidrug resistance in cancer cells. in Immunology at the Confluence of Multidisciplinary Approaches: abstract book: 2019 Dec 6-8; Belgrade, Serbia
Belgrade: Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade., 122-122.
https://hdl.handle.net/21.15107/rcub_ibiss_6040

Dinić J, Podolski-Renić A, Stanković T, Botta M, Pešić M. Novel pyrazolo[3,4-d]pyrimidine derivatives supress P-glycoprotein activity and reverse multidrug resistance in cancer cells. in Immunology at the Confluence of Multidisciplinary Approaches: abstract book: 2019 Dec 6-8; Belgrade, Serbia. 2019;:122-122.
https://hdl.handle.net/21.15107/rcub_ibiss_6040 .

Dinić, Jelena, Podolski-Renić, Ana, Stanković, Tijana, Botta, Maurizio, Pešić, Milica, "Novel pyrazolo[3,4-d]pyrimidine derivatives supress P-glycoprotein activity and reverse multidrug resistance in cancer cells" in Immunology at the Confluence of Multidisciplinary Approaches: abstract book: 2019 Dec 6-8; Belgrade, Serbia (2019):122-122,
https://hdl.handle.net/21.15107/rcub_ibiss_6040 .

TY  - CONF
AU  - Nešović, Marija
AU  - Podolski-Renić, Ana
AU  - Stanković, Tijana
AU  - Divac Rankov, Aleksandra
AU  - Fallacara, Anna Lucia
AU  - Schenone, Silvia
AU  - Botta, Maurizio
AU  - Pešić, Milica
AU  - Dinić, Jelena
PY  - 2019
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6045
AB  - Glioblastoma multiforme (GBM) are the most frequent and aggressive (WHO grade IV) brain
tumors in adults. GBM have high expression of c-Src tyrosine kinase involved in survival,
migration and invasiveness of tumor cells. Thus, c-Src emerged as a potential target for GBM
therapy. Cytotoxicity of c-Src inhibitors pyrozolo[3,4-d]pyrimidines, Si306 and its prodrug pro-Si306,
was investigated in human GBM cell line U87 and its multidrug resistant (MDR) counterpart
U87-TxR by MTT assay. Anti-migratory and anti-invasive effects of Si306 and pro-Si306 were
assessed by wound healing, gelatin degradation and transwell invasion assays. The effect of cSrc inhibitors on P-glycoprotein (P-gp) activity in U87-TxR cells was analyzed by flow cytometry. Their ability to reverse paclitaxel resistance in MDR cells was also assessed. Zebrafish model was used to evaluate anti-invasive potential of pro-Si306 on U87 xenografts in vivo. Novel c-Src inhibitors were significantly more efficient in cell growth inhibition compared to the well-known tyrosine kinase inhibitor dasatinib. The efficacy of Si306 and pro-Si306 was not affected by the MDR phenotype.
Migratory potential of U87 and U87-TxR cells was significantly decreased by both inhibitors.
The ability of cells to degrade the matrix and invade through basement membrane was also
significantly impaired upon treatment with Si306 and its prodrug. Assessment of intracellular
accumulation of fluorescent P-gp substrate showed that both compounds inhibited P-gp activity
in U87-TxR cells. Si306 and pro-Si306 also enhanced the paclitaxel efficacy in resistant
glioblastoma. In vivo pro-Si306 showed anti-invasive effect against U87 xenografts in zebrafish
model. Considering their ability to suppress migration and invasion and overcome MDR, Si306 and proSi306 could be considered in GBM treatment alone or in combination with other
chemotherapeutics.
PB  - COST Action CM1407
C3  - COST Action CM1407: Challenging organic syntheses inspired by naturefrom natural products chemistry to drug discovery: Meeting dedicated to Early career Investigators; 2019 Feb 18-19; Brussels, Belgium
T1  - The potential of c-Src inhibitors Si306 and pro-Si306 for suppressing invasion and overcoming multidrug resistance in glioblastoma
SP  - 9
EP  - 9
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_6045
ER  - 

@conference{
author = "Nešović, Marija and Podolski-Renić, Ana and Stanković, Tijana and Divac Rankov, Aleksandra and Fallacara, Anna Lucia and Schenone, Silvia and Botta, Maurizio and Pešić, Milica and Dinić, Jelena",
year = "2019",
abstract = "Glioblastoma multiforme (GBM) are the most frequent and aggressive (WHO grade IV) brain
tumors in adults. GBM have high expression of c-Src tyrosine kinase involved in survival,
migration and invasiveness of tumor cells. Thus, c-Src emerged as a potential target for GBM
therapy. Cytotoxicity of c-Src inhibitors pyrozolo[3,4-d]pyrimidines, Si306 and its prodrug pro-Si306,
was investigated in human GBM cell line U87 and its multidrug resistant (MDR) counterpart
U87-TxR by MTT assay. Anti-migratory and anti-invasive effects of Si306 and pro-Si306 were
assessed by wound healing, gelatin degradation and transwell invasion assays. The effect of cSrc inhibitors on P-glycoprotein (P-gp) activity in U87-TxR cells was analyzed by flow cytometry. Their ability to reverse paclitaxel resistance in MDR cells was also assessed. Zebrafish model was used to evaluate anti-invasive potential of pro-Si306 on U87 xenografts in vivo. Novel c-Src inhibitors were significantly more efficient in cell growth inhibition compared to the well-known tyrosine kinase inhibitor dasatinib. The efficacy of Si306 and pro-Si306 was not affected by the MDR phenotype.
Migratory potential of U87 and U87-TxR cells was significantly decreased by both inhibitors.
The ability of cells to degrade the matrix and invade through basement membrane was also
significantly impaired upon treatment with Si306 and its prodrug. Assessment of intracellular
accumulation of fluorescent P-gp substrate showed that both compounds inhibited P-gp activity
in U87-TxR cells. Si306 and pro-Si306 also enhanced the paclitaxel efficacy in resistant
glioblastoma. In vivo pro-Si306 showed anti-invasive effect against U87 xenografts in zebrafish
model. Considering their ability to suppress migration and invasion and overcome MDR, Si306 and proSi306 could be considered in GBM treatment alone or in combination with other
chemotherapeutics.",
publisher = "COST Action CM1407",
journal = "COST Action CM1407: Challenging organic syntheses inspired by naturefrom natural products chemistry to drug discovery: Meeting dedicated to Early career Investigators; 2019 Feb 18-19; Brussels, Belgium",
title = "The potential of c-Src inhibitors Si306 and pro-Si306 for suppressing invasion and overcoming multidrug resistance in glioblastoma",
pages = "9-9",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_6045"
}

Nešović, M., Podolski-Renić, A., Stanković, T., Divac Rankov, A., Fallacara, A. L., Schenone, S., Botta, M., Pešić, M.,& Dinić, J.. (2019). The potential of c-Src inhibitors Si306 and pro-Si306 for suppressing invasion and overcoming multidrug resistance in glioblastoma. in COST Action CM1407: Challenging organic syntheses inspired by naturefrom natural products chemistry to drug discovery: Meeting dedicated to Early career Investigators; 2019 Feb 18-19; Brussels, Belgium
COST Action CM1407., 9-9.
https://hdl.handle.net/21.15107/rcub_ibiss_6045

Nešović M, Podolski-Renić A, Stanković T, Divac Rankov A, Fallacara AL, Schenone S, Botta M, Pešić M, Dinić J. The potential of c-Src inhibitors Si306 and pro-Si306 for suppressing invasion and overcoming multidrug resistance in glioblastoma. in COST Action CM1407: Challenging organic syntheses inspired by naturefrom natural products chemistry to drug discovery: Meeting dedicated to Early career Investigators; 2019 Feb 18-19; Brussels, Belgium. 2019;:9-9.
https://hdl.handle.net/21.15107/rcub_ibiss_6045 .

Nešović, Marija, Podolski-Renić, Ana, Stanković, Tijana, Divac Rankov, Aleksandra, Fallacara, Anna Lucia, Schenone, Silvia, Botta, Maurizio, Pešić, Milica, Dinić, Jelena, "The potential of c-Src inhibitors Si306 and pro-Si306 for suppressing invasion and overcoming multidrug resistance in glioblastoma" in COST Action CM1407: Challenging organic syntheses inspired by naturefrom natural products chemistry to drug discovery: Meeting dedicated to Early career Investigators; 2019 Feb 18-19; Brussels, Belgium (2019):9-9,
https://hdl.handle.net/21.15107/rcub_ibiss_6045 .

TY  - JOUR
AU  - Fallacara, Ana Lucia
AU  - Zamperini, Claudio
AU  - Podolski-Renić, Ana
AU  - Dinić, Jelena
AU  - Stanković, Tijana
AU  - Nešović, Marija
AU  - Mancini, Arianna
AU  - Rango, Enrico
AU  - Iovenitti, Giulia
AU  - Molinari, Alessio
AU  - Bugli, Francesca
AU  - Sanguinetti, Maurizio
AU  - Torelli, Riccardo
AU  - Martini, Maurizio
AU  - Maccari, Laura
AU  - Valoti, Massimo
AU  - Dreassi, Elena
AU  - Botta, Maurizio
AU  - Pešić, Milica
AU  - Schenone, Silvia
PY  - 2019
UR  - https://www.mdpi.com/2072-6694/11/6/848
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3379
AB  - Overexpression of P-glycoprotein (P-gp) and other ATP-binding cassette (ABC) transporters
in multidrug resistant (MDR) cancer cells is responsible for the reduction of intracellular drug
accumulation, thus decreasing the efficacy of chemotherapeutics. P-gp is also found at endothelial
cells’ membrane of the blood-brain barrier, where it limits drug delivery to central nervous system
(CNS) tumors. We have previously developed a set of pyrazolo[3,4-d]pyrimidines and their prodrugs
as novel Src tyrosine kinase inhibitors (TKIs), showing a significant activity against CNS tumors in
in vivo. Here we investigated the interaction of the most promising pair of drug/prodrug with P-gp
at the cellular level. The tested compounds were found to increase the intracellular accumulation
of Rho 123, and to enhance the efficacy of paclitaxel in P-gp overexpressing cells. Encouraging
pharmacokinetics properties and tolerability in vivo were also observed. Our findings revealed a
novel role of pyrazolo[3,4-d]pyrimidines which may be useful for developing a new effective therapy
in MDR cancer treatment, particularly against glioblastoma.
T2  - Cancers
T1  - A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor
IS  - 6
VL  - 11
DO  - 10.3390/cancers11060848
SP  - 848
ER  - 

@article{
author = "Fallacara, Ana Lucia and Zamperini, Claudio and Podolski-Renić, Ana and Dinić, Jelena and Stanković, Tijana and Nešović, Marija and Mancini, Arianna and Rango, Enrico and Iovenitti, Giulia and Molinari, Alessio and Bugli, Francesca and Sanguinetti, Maurizio and Torelli, Riccardo and Martini, Maurizio and Maccari, Laura and Valoti, Massimo and Dreassi, Elena and Botta, Maurizio and Pešić, Milica and Schenone, Silvia",
year = "2019",
abstract = "Overexpression of P-glycoprotein (P-gp) and other ATP-binding cassette (ABC) transporters
in multidrug resistant (MDR) cancer cells is responsible for the reduction of intracellular drug
accumulation, thus decreasing the efficacy of chemotherapeutics. P-gp is also found at endothelial
cells’ membrane of the blood-brain barrier, where it limits drug delivery to central nervous system
(CNS) tumors. We have previously developed a set of pyrazolo[3,4-d]pyrimidines and their prodrugs
as novel Src tyrosine kinase inhibitors (TKIs), showing a significant activity against CNS tumors in
in vivo. Here we investigated the interaction of the most promising pair of drug/prodrug with P-gp
at the cellular level. The tested compounds were found to increase the intracellular accumulation
of Rho 123, and to enhance the efficacy of paclitaxel in P-gp overexpressing cells. Encouraging
pharmacokinetics properties and tolerability in vivo were also observed. Our findings revealed a
novel role of pyrazolo[3,4-d]pyrimidines which may be useful for developing a new effective therapy
in MDR cancer treatment, particularly against glioblastoma.",
journal = "Cancers",
title = "A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor",
number = "6",
volume = "11",
doi = "10.3390/cancers11060848",
pages = "848"
}

Fallacara, A. L., Zamperini, C., Podolski-Renić, A., Dinić, J., Stanković, T., Nešović, M., Mancini, A., Rango, E., Iovenitti, G., Molinari, A., Bugli, F., Sanguinetti, M., Torelli, R., Martini, M., Maccari, L., Valoti, M., Dreassi, E., Botta, M., Pešić, M.,& Schenone, S.. (2019). A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor. in Cancers, 11(6), 848.
https://doi.org/10.3390/cancers11060848

Fallacara AL, Zamperini C, Podolski-Renić A, Dinić J, Stanković T, Nešović M, Mancini A, Rango E, Iovenitti G, Molinari A, Bugli F, Sanguinetti M, Torelli R, Martini M, Maccari L, Valoti M, Dreassi E, Botta M, Pešić M, Schenone S. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor. in Cancers. 2019;11(6):848.
doi:10.3390/cancers11060848 .

Fallacara, Ana Lucia, Zamperini, Claudio, Podolski-Renić, Ana, Dinić, Jelena, Stanković, Tijana, Nešović, Marija, Mancini, Arianna, Rango, Enrico, Iovenitti, Giulia, Molinari, Alessio, Bugli, Francesca, Sanguinetti, Maurizio, Torelli, Riccardo, Martini, Maurizio, Maccari, Laura, Valoti, Massimo, Dreassi, Elena, Botta, Maurizio, Pešić, Milica, Schenone, Silvia, "A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor" in Cancers, 11, no. 6 (2019):848,
https://doi.org/10.3390/cancers11060848 . .

TY  - JOUR
AU  - Mori, Mattia
AU  - Vignaroli, Giulia
AU  - Cau, Ylenia
AU  - Dinić, Jelena
AU  - Hill, Richard
AU  - Rossi, Matteo
AU  - Colecchia, David
AU  - Pešić, Milica
AU  - Link, Wolfgang
AU  - Chiariello, Mario
AU  - Ottmann, Christian
AU  - Botta, Maurizio
PY  - 2014
UR  - https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201400044
UR  - https://radar.ibiss.bg.ac.rs/123456789/3886
AB  - 14-3-3 is a family of highly conserved adapter proteins that is attracting much interest among medicinal chemists. Small-molecule inhibitors of 14-3-3 protein-protein interactions (PPIs) are in high demand, both as tools to increase our understanding of 14-3-3 actions in human diseases and as leads to develop innovative therapeutic agents. Herein we present the discovery of novel 14-3-3 PPI inhibitors through a multidisciplinary strategy combining molecular modeling, organic synthesis, image-based high-content analysis of reporter cells, and in vitro assays using cancer cells. Notably, the two most active compounds promoted the translocation of c-Abl and FOXO pro-apoptotic factors into the nucleus and sensitized multidrug-resistant cancer cells to apoptotic inducers such as doxorubicin and the pan-Akt inhibitor GSK690693, thus becoming valuable lead candidates for further optimization. Our results emphasize the possible role of 14-3-3 PPI inhibitors in anticancer combination therapies.
PB  - Weinheim : Wiley-VCH
T2  - ChemMedChem
T1  - Discovery of 14‐3‐3 Protein–Protein Interaction Inhibitors that Sensitize Multidrug‐Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693
IS  - 5
VL  - 9
DO  - 10.1002/cmdc.201400044
SP  - 973
EP  - 983
ER  - 

@article{
author = "Mori, Mattia and Vignaroli, Giulia and Cau, Ylenia and Dinić, Jelena and Hill, Richard and Rossi, Matteo and Colecchia, David and Pešić, Milica and Link, Wolfgang and Chiariello, Mario and Ottmann, Christian and Botta, Maurizio",
year = "2014",
abstract = "14-3-3 is a family of highly conserved adapter proteins that is attracting much interest among medicinal chemists. Small-molecule inhibitors of 14-3-3 protein-protein interactions (PPIs) are in high demand, both as tools to increase our understanding of 14-3-3 actions in human diseases and as leads to develop innovative therapeutic agents. Herein we present the discovery of novel 14-3-3 PPI inhibitors through a multidisciplinary strategy combining molecular modeling, organic synthesis, image-based high-content analysis of reporter cells, and in vitro assays using cancer cells. Notably, the two most active compounds promoted the translocation of c-Abl and FOXO pro-apoptotic factors into the nucleus and sensitized multidrug-resistant cancer cells to apoptotic inducers such as doxorubicin and the pan-Akt inhibitor GSK690693, thus becoming valuable lead candidates for further optimization. Our results emphasize the possible role of 14-3-3 PPI inhibitors in anticancer combination therapies.",
publisher = "Weinheim : Wiley-VCH",
journal = "ChemMedChem",
title = "Discovery of 14‐3‐3 Protein–Protein Interaction Inhibitors that Sensitize Multidrug‐Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693",
number = "5",
volume = "9",
doi = "10.1002/cmdc.201400044",
pages = "973-983"
}

Mori, M., Vignaroli, G., Cau, Y., Dinić, J., Hill, R., Rossi, M., Colecchia, D., Pešić, M., Link, W., Chiariello, M., Ottmann, C.,& Botta, M.. (2014). Discovery of 14‐3‐3 Protein–Protein Interaction Inhibitors that Sensitize Multidrug‐Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693. in ChemMedChem
Weinheim : Wiley-VCH., 9(5), 973-983.
https://doi.org/10.1002/cmdc.201400044

Mori M, Vignaroli G, Cau Y, Dinić J, Hill R, Rossi M, Colecchia D, Pešić M, Link W, Chiariello M, Ottmann C, Botta M. Discovery of 14‐3‐3 Protein–Protein Interaction Inhibitors that Sensitize Multidrug‐Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693. in ChemMedChem. 2014;9(5):973-983.
doi:10.1002/cmdc.201400044 .

Mori, Mattia, Vignaroli, Giulia, Cau, Ylenia, Dinić, Jelena, Hill, Richard, Rossi, Matteo, Colecchia, David, Pešić, Milica, Link, Wolfgang, Chiariello, Mario, Ottmann, Christian, Botta, Maurizio, "Discovery of 14‐3‐3 Protein–Protein Interaction Inhibitors that Sensitize Multidrug‐Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693" in ChemMedChem, 9, no. 5 (2014):973-983,
https://doi.org/10.1002/cmdc.201400044 . .